← All stocks

EXELIXIS, INC.

EXEL No buying or selling
CIK 0000939767 #814 in the set updated 18 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

17 insiders · 0 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
MORRISSEY MICHAEL
President and CEO
3,366,335
$180.64M
+40.2%
JOHNSON DAVID EDWARD
Director
1,553,262
$83.35M
+1.8%
PAPADOPOULOS STELIOS
Director
1,197,595
$64.26M
−6.4%
Senner Christopher J.
EVP and CFO
952,317
$51.10M
+32.0%
Hessekiel Jeffrey
EVP & General Counsel
693,396
$37.21M
+9.9%
Aftab Dana
EVP, Research and Development
594,741
$31.91M
+18.6%
Peterson Amy C.
EVP Prod Dev & Med Aff & CMO
465,393
$24.97M
+44.5%
Haley Patrick J.
EVP, Commercial
357,638
$19.19M
−5.0%
WYSZOMIERSKI JACK L
Director
284,384
$15.26M
−18.6%
POSTE GEORGE
Director
127,199
$6.83M
−36.1%
Freire Maria C
Director
109,186
$5.86M
+20.0%
Hefti Brenda
SVP and General Counsel
106,762
$5.73M
+17.8%
Heyman Tomas J.
Director
50,649
$2.72M
+36.8%
Oliver Bob
Director
29,487
$1.58M
−20.3%
Smith Julie
Director
28,957
$1.55M
+168.7%
Beckerle Mary C
Director
16,079
$862.80K
−53.1%
Eckhardt Sue Gail
Director
16,079
$862.80K
−53.1%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 0
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 2 Sep 2016